All News
Filter News
Found 175 articles
-
Gastrointestinal and autoimmune company Arena Pharmaceuticals announced mixed topline results for the Phase IIb trial of its oral cannabinoid receptor type 2 (CB2) agonist olorinab.
-
Amylyx Pharmaceuticals Appoints Erin Whitney Head of Global Clinical Operations, Shauna Horvath Head of Global Marketing and Keith White Head of Global Market Access
12/21/2020
Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease and other neurodegenerative diseases, today announced the appointments of Erin Whitney to Head of Global Clinical Operations, Shauna Horvath, previously a brand strategy consultant to Amylyx, to Head of Global Marketing and Keith White to Head of Global Market Access.
-
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
-
Clinical Catch-Up: October 5-9
10/12/2020
It was a moderately busy week for clinical trial news. Here’s a look. -
Funds will also be utilized to enhance Corbus’ pipeline of novel endocannabinoid system-targeting drug candidates, and the company’s workforce will be reduced by up to 54%.
-
Topline results from a 28-week Phase IIb trial show that lenabasum, a novel oral small molecule developed by Corbus Pharmaceuticals, did not reduce the rate of new pulmonary exacerbations compared with placebo in patients with cystic fibrosis.
-
Clinical Catch-Up: September 7-11
9/14/2020
It was a busy week for clinical trial updates. Here’s a look. -
Lenabasum is an oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2).
-
Scleroderma Therapeutics Market | Key Players Analysis | Roche's Cellcept, Rituxan, Actemra, and Esbriet
8/19/2020
Global scleroderma therapeutics market is experiencing a major growth in coming years. The growth of the market is majorly driven by rising off-label use of drugs approved for symptomatic indications, for instance rheumatoid arthritis.
-
Clinical Catch-Up: August 10-14
8/17/2020
It was a very busy week for clinical trial updates. Here’s a look. -
Scleroderma Diagnostics and Therapeutics Market: Growing demand for Electrocardiogram to Propel Demand
7/13/2020
The demand within the global market for scleroderma diagnostics and therapeutics has been rising on account of advancements in the field of rheumatoid treatments, finds Transparency Market Research.
-
BioSpace Movers & Shakers, July 10
7/10/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Clinical Catch-Up: May 31-June 5
6/8/2020
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look. -
BioSpace Movers & Shakers, May 29
5/29/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Clinical Catch-Up: April 27-May 1
5/4/2020
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look. -
Viela Bio Announces Election of Rachelle Jacques to its Board of Directors
4/30/2020
Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the election of Rachelle Jacques to its Board of Directors
-
Oppenheimer to Gather Leaders, Scientists and Investors for Fall Summit Focused on Specialty Pharma and Rare Disease Companies
9/20/2019
Oppenheimer & Co. Inc. ("Oppenheimer") – a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) – will host its two-day Fall Summit Focused on Specialty Pharma and Rare Disease Companies on September 23-24, 2019 in New York.
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corbus Pharmaceuticals Holdings, Inc. - CRBP
3/13/2019
Pomerantz LLP is investigating claims on behalf of investors of Corbus Pharmaceuticals Holdings, Inc. ("Corbus" or the "Company") (NASDAQ: CRBP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
-
Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis
1/3/2019
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that they have entered into a strategic collaboration with Kaken Pharmaceutical Co., Ltd.
-
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
12/17/2018
DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a 5-year mortality rate as high as 30%